Research Article
Normal and Reversed-Phase HPTLC Methods for Simultaneous Estimation of Telmisartan and Metoprolol Succinate in Pharmaceutical Formulation
Table 3
Validation parameters.
| | Method | Method I | Method II | | Parameters | TELMI | MET | TELMI | MET |
| | Linearity (correlation coefficient) | 0.997 | 0.997 | 0.996 | 0.998 | | Slope | 3.443 | 0.381 | 0.827 | 0.660 | | Intercept | 2589 | 732.1 | 803.5 | 1135 | | Ruggedness (% RSD) | | | | | | Analyst-I () | 0.71 | 1.52 | 0.63 | 0.90 | | Analyst-II () | 0.60 | 0.96 | 0.87 | 1.14 | | Robustness [% RSD] () | | | | | | Mobile phase composition | 0.41 | 0.69 | 0.87 | 0.29 | | Duration of saturation time | 0.84 | 1.23 | 0.74 | 0.83 | | Mobile phase volume | 1.49 | 1.05 | 0.43 | 0.43 | | Development distance | 0.38 | 0.74 | 0.19 | 0.65 | | Sensitivity | | | | | | Limit of detection (ng) | 2.79 | 58.69 | 43.97 | 64.18 | | Limit of quantitation (ng) | 8.45 | 177.86 | 133.26 | 194.49 | | Precision (% RSD) | | | | | | Intraday () | 0.44–0.73 | 0.62–0.97 | 0.51–0.67 | 0.51–1.13 | | Interday () | 0.52–0.89 | 0.46–1.38 | 0.56–0.79 | 0.57–1.23 | | Repeatability () | 0.75 | 1.40 | 1.02 | 0.86 |
|
|
